Vardenafil: a novel type 5 phosphodiesterase inhibitor for the treatment of erectile dysfunction

Bibliography

• FELDMAN HA, GOLDSTEIN I, HATZICHRISTOU DG, KRANE RJ, MCKINLAY JB: Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J. Urol (1994) 151(1):54–61.
   PubMed Web of Science ®Google Scholar
• AYTA IA, MCKINLAY JB, KRANE RJ: The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. RIU Int. (1999) 84(1):50–56.
   Google Scholar
• LUE TF: Erectile dysfunction. N Engl. Med. (2000) 342(24):1802–1813.
   PubMed Web of Science ®Google Scholar
• SEFTEL AD: Challenges in oral therapy for erectile dysfunction. J. Andra (2002) 23(6):729–736.
   PubMedGoogle Scholar
• BLANDER DS, SANCHEZ-ORTIZ RF, WEIN AJ, BRODERICK GA: Efficacy of sildenafil in erectile dysfunction after radical prostatectomy. Int. J. Impot. Res. (2000) 12(3):165–168.
   PubMedGoogle Scholar
• SAENZ DE TEJADA I, ANGULO J, CUE VAS P et al.: The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int. j Impot. Res. (2001) 13(5):282–290.
   Google Scholar
• KIM NN, HUANG YH, GOLDSTEIN I, BISCHOFF E, TRAIS AM: Inhibition of cyclic GMP hydrolysis in human corpus cavernosum smooth muscle cells by vardenafil, a novel, selective phosphodiesterase Type 5 inhibitor. Life Sci. (2001) 69(19):2249–2256.
   PubMed Web of Science ®Google Scholar
• BISCHOFF E, NIEWOHNER U, HANING N, ES SAYED M, SCHENKE T: The inhibitory selectivity of vardenafil on bovine and human recombinant phosphodieasterase isoenzymes. hat. Impot. Res. (2001) 13\(Suppl. 4):541.
   Google Scholar
• GBEKOR E, BS, FAWCETT L et al.: Phosphodiesterase 5 inhibitor profiles against all human phosphodiesterase families: Implications for use as pharmacological tools. J. Urol (2002) 167\(Suppl. 4):Abstract 967.
   Google Scholar
• FRANCIS SH, CORBIN JD: Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. Can: Urol Rep. (2003) 4(6):457–465.
   PubMedGoogle Scholar
• CHOI S, O'CONNELL L, MIN K et al: Efficacy of vardenafil and sildenafil in facilitating penile erection in an animal model. J. AndroL (2002) 23(3):332–337.
   PubMed Web of Science ®Google Scholar
• BISCHOFF E, NIEWOEHNER U, HANING H, ES SAYED M, SCHENKE T, SCHLEMMER KH: The oral efficacy of vardenafil hydrochloride for inducing penile erection in a conscious rabbit model." Urol (2001) 165(4):1316–1318.
   Google Scholar
• KLOTZ T, SACHSE R, HEIDRICH A et al.: Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J. Urol (2001) 19(1):32–39.
   PubMed Web of Science ®Google Scholar
• STARK S, SACHSE R, LIEDL T et al: Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur. Urol (2001) 40(2):181–188; Discussion: 189–190.
   Google Scholar
• SACHSE R, RG, STARK S, KLOTZ T: Safety, tolerability and pharmacokinetics of BAY 38-9456 in patients with erectile dysfunction.' UroL (2000) 163:204.
   Google Scholar
• RAJAGOPALAN P. MAZZU A, XIA C, DAWKINS R, SUNDARESAN P: Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. .1. Clin. Pharmacol (2003) 43(3):260–267.
   Google Scholar
• MAZZU A, TAYLOR T, BAUER R-J et al.: A single oral dose of vardenafil had no acute effect on sperm motility in healthy males. J. Andra (2002) 23\(Suppl. 1):2.
   Google Scholar
• SHABSIGH R, KAUFMAN JM, STEIDLE C, PADMA-NATHAN R: Testosterone replacement therapy with testosterone gel 1% converts sildenafil non-responders in men with hypogonadism and erectile dysfunction who failed prior sildenafil therapy. AUA 2003 Annual Meeting, Chicago, Illinois, USA April 26 - May 1(2003) (Abstract 954).
   Google Scholar
• RADTKE M, KARL W, SEIDEL D, SCHNORBUS H, SCHREIBER A, BOBERG M: Biotransformation of [14C]-vardenafil in man. Drug Metab. Rev (2001) 33(Suppl.):114.
   Google Scholar
• STEIDLE C, PORST H, HOLLISTER A, SEGERSON T: Vardenafil demonstrated similar efficacy and tolerability among older and younger patients with marginal differences PK characteristics between age groups. Int. J. Impot. Res. (2001) 13:S63.
   Google Scholar
• KLOTZ T, BAUER R-J, ROHDE G: Effect of renal impairment on the single-dose pharmacokinetics of vardenafil 20 mg, a selective PDE5 inhibitor for the treatment of erectile dysfunction. Pharmacotherapy (2002) 22:418.
   Google Scholar
• ROHDE G, WENSING G, UNGER S: The pharmacokinetics of vardenafil, a new selective PDE5 inhibitor, are not affected by the antacid, Maalox 70. Pharmacotherapy (2001) 21(10):1254.
   Google Scholar
• ROHDE G, JORDAN P: Influence of vardenafil on blood pressure and pharmacokinetics in hypertensive patients on nifedipine therapy. Pharmacotherapy (2002) 22:418.
   Google Scholar
• MAZZU AL, NICHOLLS AJ, ZINNY M: Vardenafil, a new selective PDE-5 inhibitor, interacts minimally with nitroglycerin in healthy middle-aged male subjects. Int. J. Impot. Res. (2001) 13\(Suppl. 5):564.
   Google Scholar
• ILSON BE, SHADDINGER BC, DABIRI GA et al.: A definitive study of the effects of PDE-5 inhibitors on cardiac repolarization in middle-age males. Clin. Pharm. Ther. (2004) 75:47.
   Google Scholar
• BAUER R-J, ROHDE G, WENSING G: The interaction of alcohol with vardenafil, a potent and highly selective phosphodiesterase Type 5 inhibitor. Pharmacotherapy (2002) 22:418.
   Google Scholar
• HELLSTROM WJ, GITTELMAN M, KARLIN G et al: Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial." AndroL (2002) 23(6):763–771.
   Google Scholar
• SAENZ DE TEJADA I, GLINA S, BECHER E, ULBRICH E, and the VARDENAFIL STUDY GROUP: Vardenafil exhibits long-term efficacy and safety for up to 52 weeks. Int. J. Impot. Res. (2002) 14\(Suppl. 4):522.
   Google Scholar
• POTEMPA A-J, BERNARD I, ULBRICH E: Vardenafil improved erectile function in a 'real world' flexible-dose regimen. Int. Impot. Res. (2002) 14\(Suppl. 4):537–561.
   Google Scholar
• HATZICHRISTOU D, MONTORSI F, PORST H, BUVAT J, TAYLOR T, BANDEL T: A flexible dose regimen of vardenafil for erectile dysfunction; a placebo-controlled trial. Ear: Urol (2003) Mar\(Suppl. 2):176.
   Google Scholar
• DONATUCCI C, KARLIN G, GOLDFISCHER E et al.: Influence of age on the efficacy and safety of vardenafil, a novel phosphodiesterase-5 inhibitor, for the treatment of erectile dysfunction." Am. Geriatr. Soc. (2002) 50\(Suppl. 4):S107.
   Google Scholar
• PORST H, ROSEN R, PADMA-NATHAN H et al.: Vardenafil, a new highly selective PDE5 inhibitor, improves erectile function irrespective of the baseline severity and etiology of ED or age of patient. Eur. Urel (2001) 39\(Suppl. 5):17.
   Google Scholar
• GOLDSTEIN I, GOLDSTEIN I, YOUNG JM et al, for the VARDENAFIL DIABETES STUDY GROUP: Vardenafil, a new phosphodiesterase Type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care (2003) 26(3):777–783.
   PubMed Web of Science ®Google Scholar
• BROCK G, NEHRA A, LIPSHULTZ LI et al.: Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. Urel (2003) 170(4 Pt 1):1278–1283.
   Google Scholar
• PADMA-NATHAN H, PORST H, EARDLEY I, THIBONNIER M: Efficacy and safety of vardenafil, a selective phosphodiesterase 5 inhibitor, in men with erectile dysfunction on antihypertensive therapy. Am. J. Hypertens. (2002) 15:48A.
   PubMed Web of Science ®Google Scholar
• KLONER R, MOHAN P, SEGERSON T, THIBONNIER M, NORENBERG C, PADMA-NATHAN H: Cardiovascular safety of vardenafil in patients receiving antihypertensive medications: a post-hoc analysis of five placebo-controlled clinical trials. J. Am. Cell. Cardiel (2003) 41:276A.
   Google Scholar
• THADANI U, SMITH W, NASH S et al:The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J. Am. Cell. Carcliel (2002) 40(11):2006–2012.
   PubMed Web of Science ®Google Scholar